SIRT2 mitigates radiation-induced oral mucositis by promoting homologous recombination-mediated DNA double-strand break repair in epithelial stem cells
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Mousumi Patra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. Hauptthemen laut MEDLINE: Sirtuin 2, DNA Breaks, Double-Stranded, Stomatitis, Stem Cells. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, National Institutes of Health.
Abstract (Originalsprache)
Radiation-induced oral mucositis (RIOM) is a common and debilitating toxicity of radiotherapy for head and neck squamous cell carcinoma (HNSCC), often compromising treatment adherence and profoundly impairing patient quality of life. Despite its clinical burden, there are currently no FDA-approved therapies to prevent or treat RIOM.The underlying mechanisms remain incompletely understood but are thought to involve inflammatory responses triggered by oxidative stress and DNA damage from ionizing radiation (IR). Here, we identify SIRT2, an NAD+-dependent deacetylase, as a key modulator of RIOM susceptibility. We demonstrate that both genetic and pharmacologic activation of SIRT2 robustly protects mice from developing RIOM. Mechanistically, SIRT2 enhances homologous recombination (HR)-mediated repair of DNA double-strand breaks (DSBs), thereby preserving the epithelial stem cell population of the oral mucosa and reducing mucosal injury. Importantly, SIRT2 activation—achieved via NAD+ supplementation in vitro or nicotinamide riboside (NR) in vivo—does not compromise the tumoricidal efficacy of IR in HNSCC models. These findings reveal a previously unrecognized protective role for SIRT2 in mucosal radiation injury and establish its activation as a promising, non-oncogenic therapeutic strategy to mitigate RIOM in patients receiving radiotherapy for head and neck cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
- Department of Radiation Oncology, Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. Electronic address: fxia@uams.edu.
Förderung
- NCI NIH HHS
- UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES
- National Institutes of Health
Zitieren
APA
Patra, M., Sadhukhan, R., Allen, E., Kalantari, F., Allam, H., & Xia, F. (2026). SIRT2 mitigates radiation-induced oral mucositis by promoting homologous recombination-mediated DNA double-strand break repair in epithelial stem cells. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218239
Vancouver
Patra M, Sadhukhan R, Allen E, Kalantari F, Allam H, Xia F. SIRT2 mitigates radiation-induced oral mucositis by promoting homologous recombination-mediated DNA double-strand break repair in epithelial stem cells. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218239
BibTeX
@article{Patra2026,
author = {Patra, Mousumi and Sadhukhan, Ratan and Allen, Eva and Kalantari, Faraz and Allam, Heba and Xia, Fen},
title = {SIRT2 mitigates radiation-induced oral mucositis by promoting homologous recombination-mediated DNA double-strand break repair in epithelial stem cells},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218239}
}
EUVIMED